Episode 4: BOIN Design in Clinical Trials episode artwork

EPISODE · Jul 18, 2025 · 11 MIN

Episode 4: BOIN Design in Clinical Trials

from QCast: Data-Driven Dialogue in Drug Development · host Quanticate

In this QCast episode, join co-hosts Jullia and Tom as they unpack the Bayesian Optimal Interval, or BOIN, design for early-phase oncology studies. You'll hear how BOIN blends Bayesian reasoning with simple decision rules, why regulators now call it 'fit for purpose,' and how sponsors are using it to speed up dose-finding while keeping patient safety front and centre.Key TakeawaysBOIN design is a model-assisted Bayesian dose-escalation method with pre-defined escalation, de-escalation and safety rules.Core concepts involve setting a target toxicity rate, calculating helper rates at 60% and 140%, deriving decision limits via Bayesian posteriors and including a 95% safety stop.Compared to the 3+3 method, BOIN locates the true MTD more accurately, allows flexible cohort sizes, and runs off a simple printed decision table.Operational essentials include embedding the decision table in your protocol, aligning toxicity assessment windows (or using time-to-event BOIN), training site teams with examples and running light simulations.Common pitfalls are choosing an unrealistic toxicity target, treating BOIN as 'set-and-forget,' and adding extensions without recalculating the decision boundaries.🔗 Learn More & Get Support: Visit quanticate.com to explore our biometrics services and discover how we can support your next clinical trial. 📝 Episode Notes & Transcript: Find show notes, resources, and a full transcript at quanticate.com/podcast.🔔 Stay Connected: Subscribe to QCast on Apple Podcasts, Spotify, or your favourite platform to never miss an episode.About QuanticateFounded in 1994, Quanticate is a biometrics-focused CRO with over 30 years' experience delivering expert clinical and post-marketing data services worldwide. Specialising in the collection, management, standardisation, analysis, and reporting of data, we support pharma and biotech companies globally with high-quality solutions for clinical development. We specialise in:Clinical Data Capture & ManagementBiostatistics & Statistical ConsultancyStatistical Programming & PK/PD AnalysisMedical Writing & PharmacovigilanceRegulatory & Submission SupportAI & AutomationPost-Marketing Safety & Real-World DataQuanticate is committed to delivering expertise and solutions that drive the success of clinical development worldwide.

Episode metadata supplied by the publisher feed · Published Jul 18, 2025

Embed this episode

In this QCast episode, join co-hosts Jullia and Tom as they unpack the Bayesian Optimal Interval, or BOIN, design for early-phase oncology studies. You'll hear how BOIN blends Bayesian reasoning with simple decision rules, why regulators now call it 'fit for purpose,' and how sponsors are using it to speed up dose-finding while keeping patient safety front and centre. Key Takeaways BOIN design is a model-assisted Bayesian dose-escalation method with pre-defined escalation, de-escalation and s...

Distinct summary based on available episode metadata or transcript content.

Ready to play

Episode 4: BOIN Design in Clinical Trials

0:00 11:12

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of QCast: Data-Driven Dialogue in Drug Development?

This episode is 11 minutes long.

When was this QCast: Data-Driven Dialogue in Drug Development episode published?

This episode was published on July 18, 2025.

Can I download this QCast: Data-Driven Dialogue in Drug Development episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!